Table 2.
Cell type | Immune cell | Mechanism | Effect | Reference |
---|---|---|---|---|
BM-MSC | B cell | inhibition of BAFF production | suppress the excessive activation of B-cells | (76) |
MSCs | B cell | directly contacting with T cells | inhibit B cell differentiation, maturation, | (77) |
MSCs | B cell | by depleting tryptophan in the inflammatory microenvironment of human body | inhibits the proliferation, excessive activation and maturation of B cells | (78) |
MSC | Breg cell | through SDF-1-CXCR7 axis | increased regulation B (Breg) | (77) |
MSC-EVs miRNA-155-5p | B cell | targeting PI3K/AKT signaling pathway | inhibit activation of B cell | (79) |
MSC | B cell | increased expression of CCL2 by CCL2-MST1-mTOR-STAT1 mediated metabolic signaling pathway | prevent inhibition differentiation, proliferation, and antibody secretion of B-cell | (80) |
MSC | B cell | inhibit expression of maturation protein-1 | inhibit B cells terminal differentiation | (81) |
GMSCs | B cell | targeting of CD39-CD73 signaling pathway | suppressing B cells and produce autoantibodies | (82) |
MSC, Mesenchymal stem cells; BM-MSC, bone marrow Mesenchymal stem cells; GMSC, gingiva derived MSCs; SDF-1-CXCR7, Stromal-derived factor-1 and its receptor C-X-C chemokine receptor-7; Breg, regulation B cell; CCL2, chemokine CC motif ligand 2; CCL2-MST1-mTOR-STAT1, chemokine CC motif ligand 2-mammalian Sterile 20-like kinase 1- media Time of Repair-signal transducerand activator of transcription 1.